Modern concepts of biosimilars in hematology and oncology
https://doi.org/10.17650/1818-8346-2013-8-1-59-64
Abstract
Biologics are large protein or polypeptide molecules produced by living organisms, which largely determine the efficiency of modern anticancer
therapy. Biological products that destroy cancer cells and protect normal patient tissue led to progress in the treatment of breast cancer, colon cancer, kidney cancer, malignant lymphomas and other diseases. But the high cost and complexity of production limit their use. The expiration of patent protection for a number of biological products resulting to the possibility of reduces their costs when issuing an alternative manufacturer. At the same time, biosimilars are produced by living cells (as the original protein molecules), which led to serious difficulties in reaching their identity. The European Union has developed special registration rules for these preparations in order to avoid lack of efficacy or increased toxicity. They include regulations to determine the quality of biological products, requirements for pre-clinical and clinical studies, according to its specific characteristics, as well as the requirements for pharmacovigilance. Implementation of such a strategy has to register in the EU several biosimilars of granulocyte colonytimulating factor. For one of them – Zarzio – in several clinical studies fully comparable efficacy and tolerability with the original preparation was shown, thus providing a significant reduction of treatment cost with equal efficacy and toxicity.
About the Author
V. V. Ptushkin
Dmitry Rogachev Federal Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia
Russian Federation
Russian Federation
References
1. Center for Biologics Evaluation and Research (2007-10-29). “What is a biological product?” U.S. Food and Drug Administration. Retrieved 2007-12-17.
2. Avidor Y., Mabjeesh N.J., Matzkin H. Biotechnology and drug discovery: from bench to bedside. South Med J 2003;96:1174–86.
3. Guide to Biological Medicines Guide to Biological Medicines http://www. europabio.org/sites/default/files/report/guide_to_biological_medicines_a_focus_on_biosimilar_medicines.pdf.
4. Cheson B.D., Leonard J.P. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008;359:613–26.
5. Crommelin D.J., Bermejo T., Bissig M. et al. Pharmaceutical evaluation of biosimilars: important differences from generic low-molecular weight pharm. Eur J Hosp Pharm Sci 2005;1:11–7.
6. European Medicines Agency, Committee for Medicinal Products for Human Use. Biosimilar Guidelines. https://www.ema.europa.eu/ema/ index.jsp?curlpages/ regulation/general/general_content_000408.jsp& murlmenus/regulations/regulations.jsp&midWC0b01ac058002958c.
7. Accessed October 20, 2012.
8. Combe C., Tredree R.L., Schellekens H. Biosimilar epoetins: an analysis based on recently implemented European Medicines Evaluation Agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy 2005;25:954–62.
9. European Medicines Agency. Annex to guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing recombinant granulocyte colony stimulating factor
10. (G-CSF) 2006. http://www.emea.europa.eu/pdfs/human/biosimilar/3132905en.pdf.
11. Deechongkit S., Aoki K.H., Park S.S. et al. Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex. J Pharm Sci 2006;95:1931–43.
12. U.S. Food and Drug Administration. Draft guidance on biosimilar product development. http://www.fda.gov/Drugs/DevelopmentApproval Process/HowDrugsare DevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/default.htm. Accessed October 20, 2012.
13. Cri-report - Risk – Reward of Developing a Herceptin Biosimilar – A Thorough Assessment. http://www.basearticles.com/Art/1026247/24/Crireport-- Risk--Reward-of-Developing-a-Herceptin-Biosimilar--A-Thorough-Assessment.html.
14. Boven K., Stryker S., Knight J. et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005 Jun;67(6):2346–5398.
15. Bodey G.P., Buckley M., Sathe Y.S. et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328–40.
16. Lyman G.H., Lyman C.G., Sanderson R.A. et al. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Nattl Cancer Inst 1993;85:488–93.
17. Kuderer N.M., Dale D.C., Crawford J. et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. JCO 2007;25:3158–67.
18. Lyman G.H., Dale D.C., Crawford J. et al. Incidence and predictors of low doseintensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. JCO 2003;21:4524–31.
19. Sörgel F., Lerch H., Lauber T. Physicochemical and biologic comparability of a biosimilar granulocyte colonystimulating factor with its reference product. BioDrugs 2010;24:347–57.
20. Gascon P., Fuhr U., Sörgel F. et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol 2010;21:1419–29.
21. Green M.D., Koelbl H., Baselga J. et al. A randomized double-blind multicenter phase III study of fixed-dose singleadministration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29–35.
22. Holmes F.A., O’Shaughnessy J.A., Vukelja S. et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727–31.
23. Verpoort K., Möhler T.M. A non-interventional study of biosimilar granulocyte colony- stimulating factor as prophylaxis for chemotherapyinduced neutropenia in a community oncology centre. Ther Adv Med Oncol 2012;4(6):289–93.
Review
For citations:
Ptushkin V.V. Modern concepts of biosimilars in hematology and oncology. Oncohematology. 2013;8(1):59-64. (In Russ.) https://doi.org/10.17650/1818-8346-2013-8-1-59-64
Views:
10010
Email this article 